FOXP3 (forkhead box P3; HGNC:6106, NCBI Gene 50943) is the gene on chromosome Xp11.23 encoding the forkhead transcription factor that programs regulatory T cells (Tregs) — the master switch of immune tolerance. Germline mutations cause IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked): boys lacking functional FOXP3 develop type-1 diabetes, eczematous enteritis, and autoimmune disease in infancy. The FOXP3 protein page holds the mechanism and pharmacology; this page covers the locus and genetics.
Approved Symbol
FOXP3 (HGNC:6106)
Chromosomal Locus
Xp11.23
Encoded Product
FOXP3 — a 47-kDa forkhead transcription factor (431 aa), see protein page
Genomic organization: 12 exons; the zinc-finger/leucine-zipper and forkhead domains carry IPEX mutations — the DNA-binding forkhead losses the most severe; X-linked inheritance explaining the affected-boy, carrier-mother pedigree (and the skewing of X-inactivation in carriers toward the wild-type allele).
Expression: CD4+ regulatory T cells (the classic CD4+CD25+FOXP3+ surface definition); the promoter's CNS2 enhancer is demethylated in stable thymic Tregs — the epigenetic commitment that distinguishes natural from induced Tregs.
Molecular Function & Pathways
Treg programming: FOXP3's gene program — CTLA-4 induction, IL2 consumption, inhibitory cytokines — is detailed on the protein page; the gene-level regulatory network (IL2Rα/STAT5 inducing FOXP3 expression in peripherally induced Tregs) closes the loop between cytokine input and lineage commitment.
Autoimmunity's genetic proof: Scurfy mouse (the FOXP3 frameshift) and IPEX (human) — tolerance's single-gene dependency; FOXP3+ Treg deficiency or dysfunction implicated in autoimmunity broadly and in tumor immune evasion (intratumoral Tregs suppressing anti-tumor responses).
Clinical & Therapeutic Significance
Clinical genetics: IPEX syndrome — neonatal diabetes, severe enteropathy, eczema, autoimmune cytopenias; treated with immunosuppression and hematopoietic stem-cell transplantation (the gene's curative reset); FOXP3 polymorphisms modifying polygenic autoimmune risk.
Cell therapy: Ex vivo expanded autologous Tregs (FOXP3+ viability-sorted) in type-1 diabetes, transplantation, and autoinflammation trials; checkpoint-inhibitor responses' correlation with intratumoral FOXP3+ Treg numbers — the marker's double life as tolerance's badge and evasion's shield.